A prospective study (15) showed that high-sensitivity cardiac troponin T (hs-cTnT) and NT-proBNP levels increased in breast cancer patients treated with anthracycline drugs and/or trastuzumab drugs and were associated with an increased risk of CTRCD. This evidence concerns the gene TNNT2 and breast carcinoma.